Evidence map›Paper›PMID 36073950›Full record

Trial reportJapanese journal of clinical oncology2022

Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.

Tadao Ishida, Shigeki Ito, Junji Tanaka, Michihiro Uchiyama, Yawara Kawano, Philippe Moreau, Thomas Martin, Marie-Laure Risse, Keisuke Tada, Kenshi Suzuki and 1 more

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Japanese journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 4 countries.

Tadao IshidaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Shigeki ItoDivision of Hematology & Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan.
Junji TanakaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Michihiro UchiyamaDepartment of Hematology, Japanese Red Cross Society, Suwa Hospital, Suwa, Japan.
Yawara KawanoDepartment of Hematology, Kumamoto University Hospital, Kumamoto, Japan.
Philippe MoreauDepartment of Hematology, University Hospital of Nantes, Nantes, France.
Thomas MartinDepartment of Medicine, University of California, San Francisco, CA, USA.
Marie-Laure RisseSanofi, Research and Development, Vitry-Sur-Seine, France.
Keisuke TadaSanofi, Research and Development, Tokyo, Japan.
Kenshi SuzukiMyeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan.
Kenichi IshizawaDepartment of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan.ORCID 0000-0003-4911-8889
Japanese Red Cross Medical Center · JPCentre Hospitalier Universitaire de Nantes · FRIwate Medical University · JPKumamoto University Hospital · JPSanofi (France) · FRSanofi (Japan) · JPSuwa Red Cross Hospital · JPTokyo Women's Medical University · JPUniversity of California, San Francisco · USYamagata University · JP

Funding

Sanofi
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneHumansJapanOligopeptidesAntibodies, Monoclonal, HumanizedcarfilzomibDexamethasoneisatuximabOligopeptides

Identifiers

PMID36073950
PMCPMC9721457
OpenAlexW4294991584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.